telinavir

Telinavir is a synthetic small molecule classified as an HIV protease inhibitor. It was developed primarily for the treatment of HIV infections and functions by inhibiting the activity of the HIV-1 protease enzyme, which is essential for viral maturation. By binding to the active site of this enzyme through non-covalent interactions (including hydrogen bonds and π–π stacking), telinavir prevents cleavage of viral polyproteins, resulting in immature and non-infectious viral particles. Telinavir reached Phase I/II clinical trials but did not demonstrate sufficient antiviral activity in humans despite being well tolerated; as a result, its development was discontinued. The drug was originally developed by Pfizer[1][2][3][4][6][8].

Other names

telinavirSC 52151SC52151SC-52151NSC-670881NSC670881NSC 670881